共 50 条
[31]
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
[J].
Cancer Chemotherapy and Pharmacology,
2020, 86
:347-359
[32]
Combined Therapy with Rituximab Plus Cyclophosphamide/Vincristine/Prednisone for Sjogren’s Syndrome-Associated B-Cell Non-Hodgkin’s Lymphoma
[J].
Clinical Reviews in Allergy & Immunology,
2008, 34
:80-84